Dermatol. praxi. 2021;15(2):89-93 | DOI: 10.36290/der.2021.017

Risankizumab in the treatment of erythrodermic form of psoriasis in patient with associated sclerodermia

MUDr. Jan Šternberský, Ph.D., MUDr. Martin Tichý, Ph.D.
Klinika chorob kožních a pohlavních LF UP a FN Olomouc

Risankizumab is one of the newest biologic drugs used for the treatment of severe forms of psoriasis. It is humanized antibody aimed against p19 subunit of interleukin 23, which is the key initiating cytokin in the pathogenesis of psoriasis. Risankizumab has got excellent therapeutic response with longterm effect not only in clinical trials, but also in the real clinical practice. Up to date safety data are also very favorable. The case report describes excellent effect of risankizumab in the treatment of erythrodermic form of psoriasis in patient with associated sclerodermia.

Keywords: risankizumab, erythrodermic psoriasis, sclerodermia, interleukin 23.

Published: September 2, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šternberský J, Tichý M. Risankizumab in the treatment of erythrodermic form of psoriasis in patient with associated sclerodermia. Dermatol. praxi. 2021;15(2):89-93. doi: 10.36290/der.2021.017.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Skyrizi, Souhrn informací o přípravu, datum poslední revize textu 15. 10. 2020.
    2. Torres T. Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab. Drugs. 2017 Sep; 77(14): 1493-1503. doi: 10.1007/s40265-017-0794-1. PMID: 28770513. Go to original source... Go to PubMed...
    3. Cetkovská P, Kojanová M, Arenberger P, Fabianová J. Současný stav moderní léčby psoriázy - aktualizovaná doporučení ČDS JEP k cílené léčbě závažné chronické psoriázy. Cesko-Slovenska Dermatologie. 2019; 94(4): 135-162. 28p.
    4. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018; 392(10148): 650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. PMID: 30097359. Go to original source... Go to PubMed...
    5. Reich K, Gooderham M, Thaçi D, Crowley JJ, Ryan C, Krueger JG, Tsai TF, Flack M, Gu Y, Williams DA, Thompson EHZ, Paul C. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019; 394(10198): 576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4. Erratum in: Lancet. 2019 Jul 16: PMID: 31280967. Go to original source... Go to PubMed...
    6. Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, Geng Z, Paul C. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021; 184(1): 50-59. doi: 10.1111/bjd.19341. Epub 2020 Sep 6. PMID: 32594522; PMCID: PMC7983954. Go to original source... Go to PubMed...
    7. Papp KA, et al. 2020 Poster P1366 presented at the 29th European Academy of Dermatology and Venereology Congress, 29-31 October 2020, EADV Virtual Congress.
    8. Gordon K, et al. Poster 16332, Pooled long-term safety analysis of risankizumab in patients with moderate-to-severe psoriasis, presented at AAD 2020. Go to original source...
    9. Leonardi C, et al. P9891, presented at the American Academy of Dermatology (AAD) Annual Meeting; 1-5 March 2019; Washington DC, US; 3. Gordon K, et al.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.